| __timestamp | Celldex Therapeutics, Inc. | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 101881000 | 60987000 |
| Thursday, January 1, 2015 | 4011000 | 125542000 |
| Friday, January 1, 2016 | 102026000 | 210460000 |
| Sunday, January 1, 2017 | 96171000 | 275119000 |
| Monday, January 1, 2018 | 66449000 | 409539000 |
| Tuesday, January 1, 2019 | 42672000 | 547758000 |
| Wednesday, January 1, 2020 | 42534000 | 736300000 |
| Friday, January 1, 2021 | 3068000 | 904200000 |
| Saturday, January 1, 2022 | 1400000 | 1080300000 |
| Sunday, January 1, 2023 | 3008000 | 1262200000 |
| Monday, January 1, 2024 | 1530500000 |
Data in motion
In the ever-evolving landscape of biotechnology, understanding the cost of revenue is crucial for assessing a company's financial health. Over the past decade, Vertex Pharmaceuticals Incorporated has demonstrated a remarkable upward trend in its cost of revenue, surging by over 1,900% from 2014 to 2023. This growth reflects Vertex's expanding operations and increased production capabilities. In contrast, Celldex Therapeutics, Inc. has experienced a more volatile trajectory, with its cost of revenue peaking in 2016 and then declining by approximately 97% by 2023. This fluctuation may indicate strategic shifts or operational challenges within Celldex. The data highlights the contrasting financial strategies of these two biotech giants, offering insights into their market positioning and future potential. As the industry continues to innovate, monitoring these financial metrics will be key to understanding the competitive dynamics at play.
Cost of Revenue Trends: Eli Lilly and Company vs Celldex Therapeutics, Inc.
Amgen Inc. vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Vertex Pharmaceuticals Incorporated vs BioMarin Pharmaceutical Inc.
Analyzing Cost of Revenue: Vertex Pharmaceuticals Incorporated and Pharming Group N.V.
Vertex Pharmaceuticals Incorporated vs Amneal Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Vertex Pharmaceuticals Incorporated and PTC Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs MorphoSys AG
Cost of Revenue: Key Insights for Vertex Pharmaceuticals Incorporated and Vericel Corporation
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs Ligand Pharmaceuticals Incorporated
Cost of Revenue: Key Insights for Iovance Biotherapeutics, Inc. and Celldex Therapeutics, Inc.
Analyzing Cost of Revenue: Celldex Therapeutics, Inc. and Viridian Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Celldex Therapeutics, Inc. vs MiMedx Group, Inc.